JP2024512260A5 - - Google Patents

Info

Publication number
JP2024512260A5
JP2024512260A5 JP2023550552A JP2023550552A JP2024512260A5 JP 2024512260 A5 JP2024512260 A5 JP 2024512260A5 JP 2023550552 A JP2023550552 A JP 2023550552A JP 2023550552 A JP2023550552 A JP 2023550552A JP 2024512260 A5 JP2024512260 A5 JP 2024512260A5
Authority
JP
Japan
Prior art keywords
cancer
antigen
binding molecule
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023550552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512260A (ja
JP7827737B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/054123 external-priority patent/WO2022175474A1/en
Publication of JP2024512260A publication Critical patent/JP2024512260A/ja
Publication of JP2024512260A5 publication Critical patent/JP2024512260A5/ja
Application granted granted Critical
Publication of JP7827737B2 publication Critical patent/JP7827737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023550552A 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子 Active JP7827737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202101681W 2021-02-19
SG10202101681W 2021-02-19
PCT/EP2022/054123 WO2022175474A1 (en) 2021-02-19 2022-02-18 Vegfa-binding molecules

Publications (3)

Publication Number Publication Date
JP2024512260A JP2024512260A (ja) 2024-03-19
JP2024512260A5 true JP2024512260A5 (https=) 2024-11-14
JP7827737B2 JP7827737B2 (ja) 2026-03-10

Family

ID=80685523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023550275A Pending JP2024513644A (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子
JP2023550552A Active JP7827737B2 (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023550275A Pending JP2024513644A (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子

Country Status (9)

Country Link
US (2) US20240228602A9 (https=)
EP (2) EP4294839A1 (https=)
JP (2) JP2024513644A (https=)
KR (2) KR20230165902A (https=)
CN (2) CN117242092A (https=)
AR (1) AR124917A1 (https=)
AU (2) AU2022223337A1 (https=)
CA (2) CA3208389A1 (https=)
WO (2) WO2022175481A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119790077A (zh) * 2022-09-14 2025-04-08 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
AU2023340044A1 (en) * 2022-09-14 2025-04-03 Quaerite Biopharm Research (Beijing) Co., Ltd. Anti-vegfa antibody or antigen-binding fragment thereof and use thereof
CN119039450A (zh) * 2023-05-22 2024-11-29 上海君实生物医药科技股份有限公司 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP5987057B2 (ja) * 2011-07-27 2016-09-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
WO2016072938A1 (en) 2014-11-05 2016-05-12 Nanyang Technological University Stabilized and autonomous antibody vh domain
EP3078674B1 (en) * 2015-01-06 2020-09-23 Zhuhai Essex Bio-pharmaceutical Co., Ltd. Anti-vegf antibody
WO2018126317A1 (en) * 2017-01-05 2018-07-12 Helix Biopharma Corporation Vegfr-2 car immune cells to treat cancers
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用

Similar Documents

Publication Publication Date Title
JP2024512260A5 (https=)
JP2022516505A (ja) 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
AU2010247464B2 (en) Humanized AXL antibodies
WO2019042119A1 (zh) 抗人cd47抗体及其用途
JP2021514664A5 (https=)
CN103189392B (zh) ErbB3结合抗体
JP2024091842A (ja) 抗ｃｄ３抗体及び該抗体を含む分子
AU2010248365A1 (en) Anti-AXL antibody
IL302932B1 (en) Anti-garp antibodies, nucleotides encoding them, vectors, cells and compositions containing them, methods for their preparation and uses thereof
JP2013502913A5 (https=)
EP4523704A1 (en) Camptothecin derivative and ligand-drug conjugate
JP2013165711A5 (https=)
JP2024513644A5 (https=)
BR112020001657A2 (pt) Anticorpo contra cd147 humana, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso do anticorpo ou do fragmento de ligação a antígeno,polinucleotídeo, vetor de expressão, célula hospedeira, método para produzir o anticorpo ou o fragmento de ligação a antígeno do mesmo, para prognosticar aresponsividade ao tratamento contra o câncer e para selecionar sujeitos para o tratamento contra o câncer, kit para determinar a responsividade ao tratamento contra o câncer, complexo de anticorpo-fármaco, e, anticorpo biespecífico
CA2947602A1 (en) Methods for characterizing and treating acute myeloid leukemia
IL274008B1 (en) Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment
JP2023525991A5 (https=)
JP2021524032A (ja) Ｇａｓｐ−１顆粒を標的とする結合性タンパク質及びキメラ抗原受容体ｔ細胞並びにそれらの使用
JP7378088B2 (ja) ｈＥＲＧ１およびｈＥＲＧ１／インテグリンβ１に結合する単一特異性および二重特異性抗体
JP2022524175A (ja) Ｅｌｔｄ１に対するモノクローナル抗体及びその使用
JP2024540062A5 (https=)
JP2024547122A5 (https=)
JP2024534661A5 (https=)
JP2024543828A5 (https=)
Vaisitti et al. Cationization of monoclonal antibodies: another step towards the" magic bullet"?